Cilta-cel Approval Requested in Japan for Heavily-treated Myeloma
Janssen has submitted an application to regulators in Japan seeking the approval of ciltacabtagene autoleucel, an investigational CAR T-cell therapy also known as…
News
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone,…
GC012F, CAR-T Cell Therapy Candidate, Granted FDA Orphan Drug Status
Gracell Biotechnologies’ investigational new treatment for multiple myeloma, GC012F, has been named an orphan drug by the U.S. Food and Drug Administration (FDA).
1st Patient Enrolled in Phase 1 Trial of Antibody Therapy BHV-1100
Biohaven Pharmaceuticals has begun enrolling patients in its Phase 1a/1b trial testing the company’s antibody-recruiting molecule (ARM) called BHV-1100. The trial (NCT04634435) seeks…
Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial
The optimal dosing of tasquinimod, Active Biotech’s experimental oral therapy for adults with relapsed or refractory multiple myeloma, has been determined in a…
Blenrep-nirogacestat Combo Moves to Dose-testing Phase 2 of Trial
After promising early results, a sub-study of the DREAMM-5 platform trial is moving forward to its next phase to test a combination of Blenrep…
FDA Expects Decision on Cilta-cel Approval by February 2022
The U.S. Food and Drug Administration (FDA) is expected to decide by the end of February whether or not to approve ciltacabtagene autoleucel, known as…
Xpovio Open to Advanced Myeloma Patients Outside US via Access Program
People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed…
C4 Therapeutics Readying to Open Phase 1/2a Trial of CFT7455
C4 Therapeutics is preparing to launch a clinical trial testing its lead investigational therapy CFT7455 in multiple myeloma and other blood cancers. The…
Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse
People with blood type O are significantly less likely to develop multiple myeloma, but those who do are…
